Condition: Multiple System Atrophy · Sponsor: Alterity Therapeutics
This multicenter open-label extension study conducted in France is designed to provide ATH434 orally BID to eligible patients who completed the Phase 2 study ATH434-201, and who may benefit from this treatment according to the evaluation by the Investigator.
This description comes directly from the study's public registry record.
Alterity Clinical Trials · +1 888-556-7582 · clinicaltrials@alteritytx.com
Always discuss trial participation with your own doctor first.
| Hôpital Pierre-Paul Riquet | Toulouse, Midi-Pyrenees, France | — |
| Centre Hospitalier Universitaire de Bordeaux | Bordeaux, New Aquitaine, France | — |
| Hôpital de la Timone | Marseille, Provence-Alpes-Côte d'Azur Region, France | — |
| Hôpital Universitaire Pitié Salpêtrière | Paris, Île-de-France Region, France | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07729852